7 Global Health Equity Highlights in 2021 7 Social: Global Health Equity • Achieved progress in global health equity against the 10 Health for Humanity 2025 Goals that advance global health equity, demonstrating performance on track to deliver by 2025. • Demonstrated leadership in access to medicines , ranking in the top three in the 2021 Access to Medicine Index (ATMI), a position held for more than a decade. • Leveraged data science using artificial intelligence, machine learning and digital health to help develop more and better therapies for patients and innovate faster across multiple platforms including enhancing clinical trials, finding early markers of disease, enabling targeted therapies and improving global surgery outcomes. • Demonstrated 75 percent efficacy in preventing severe/critical COVID-19 at least 28 days following vaccination of a single-dose of our COVID-19 vaccine through our Phase 3 ENSEMBLE clinical trial and advanced equitable access by providing our vaccine globally at a not-for-profit price, shipping approximately 70% of our global vaccine supply to low- and middle-income countries. • Achieved a significant milestone in our HIV drug development with U.S. Food and Drug Administration approval of the world’s first long-acting injectable HIV treatment regimen that replaces a daily oral regimen with injections administered every one or two months, easing the burden of medication and facilitating adherence. We also commenced funding for a multiyear pilot program in Uganda to test the feasibility of delivering lifesaving HIV treatments using customized medical drones. Global Health Equity Best Practices in 2021 • Announced new commitments to combat tuberculosis (TB), in support of global efforts to find and deliver care to the millions of people living with TB who have not yet been diagnosed. We also launched the J&J Centers for Global Health Discovery to advance early-stage science for developing innovations to address diseases that disproportionately impact the world’s most vulnerable people, including TB, flavivirus, and antimicrobial resistance (AMR). • Completed the full vaccination of more than 200,000 Rwandans against Ebola as part of the Government of Rwanda’s UMURINZI campaign. This vaccination program also represented the first large use case of the digital-enabled Vaccination Monitoring Platform. • Surpassed a total of 2 billion cumulatively donated doses of VERMOX (mebendazole) , our medicine to treat intestinal worm infections. In 2021, we donated over 220 million doses of VERMOX in chewable and tablet formulations. • Advanced several initiatives in Our Race to Health Equity against our $100 million five-year U.S. commitment to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color. • Named one of the top three companies in the 2021 AMR Benchmark , developed by the independent Access to Medicine Foundation, for the third year in a row. In 2021, 180 million doses of our COVID-19 vaccine were shipped to the African Union, COVAX and South Africa through advanced purchase agreements and country donations. 731,000 3,200 nurses, midwives and community health workers reached though our Center for Health Worker Innovation obstetric fistula repair surgeries supported 50,000 community health workers in Rwanda supported with a unique mental health training program $6.69 million products donated for disaster relief $2.738 billion cash and products donated globally 21 products on the WHO Model List of Essential Medicines